Some individuals are genetically optimized for lower-dose GLP-1 therapy and see excellent results at 1.0 mg weekly, while others benefit from reaching 2.4 mg
sgRNA constructs and gene expressing codon optimized (OPT) plasmid constructs sgRNA control and constructs against CBS and L2HGDH were designed targeting GTATTACTGATATTGGTGGG (sgControl) (#230080, Addgene), GGAGCAGACAACCTACGAGG (sg CBS -1) (#230081, Addgene), TGGCAGTGCTGGCAGCACGG (sg CBS -2) (#230082, Addgene), GATATAGTCATCGTTGGTGG (sg L2HGDH -1) (#230083, Addgene), and CACCAGACTGGACATAACAG (sg L2HGDH -2) (#230084, Addgene) and constructed in lentiCRISPR v2-Blast (#83480, Addgene) for Blasticidin selection at a final concentration of 5 g/ml
Summary: GLP-1 receptor agonists do not directly cause sweating, but some patients report changes in perspiration patterns due to indirect factors such as gastrointestinal side effects, hypoglycaemia when combined with other diabetes medications, or autonomic responses to nausea
T.DentonT
